Moderna and European Commission Amend COVID-19 Vaccine Agreement
Moderna and the European Commission have amended their agreement to convert contractually agreed doses of Moderna’s COVID-19 vaccine to the company’s Omicron-containing bivalent vaccines for supply in 2022.
Moderna announced on August 9, 2022 an amendment to its agreement with the European Commission (EC) to convert contractually agreed doses of Moderna’s COVID-19 vaccine to its Omicron-containing bivalent vaccines for supply in 2022, pending regulatory approval. The EC has also agreed to purchase an additional 15 million doses of the Omicron-containing vaccine booster candidates from Moderna.
Under the agreement, all remaining contractually agreed doses of Moderna’s SPIKEVAX will be converted to Omicron-containing bivalent vaccines, pending approval by the European Medicines Agency (EMA). Contractually scheduled doses in July and August of SPIKEVAX will be deferred to later in 2022.
"The European Commission and Moderna have been steadfast partners in the fight against the COVID-19 pandemic. This agreement highlights the EC's trust in our mRNA platform and next-generation bivalent COVID-19 vaccines," said Stéphane Bancel, CEO of Moderna, in a press release. "Participating member states will now have access to Omicron-containing vaccine booster candidates, and protection against COVID-19, heading into the winter season."
Source: Moderna
